OPA1 and acute myeloid leukemia: Next, we depleted MFN2 or OPA1 using mCherry-tagged constitutive shRNAs in leukemic cells from patients with AML amplified in vivo using patient-derived xenograft (PDX) assays [25], or in normal human CD34+ hematopoietic progenitor cells (Fig. 1F).